The creation of retatrutide, a novel dual activator targeting both GLP-1 and GIP receptors, involves a complex several-stage chemical process. Early routes focused on amino acid chain section coupling, utilizing solid-phase production methodologies to build the long amino acid sequence. Subsequent investigation has explored different approaches, in